ONO PHARMACEUTICAL : Amgen Receives Positive CHMP Opinion to Extend Indication of Kyprolis® (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma (49.6KB)

ONO AMG 416 - Partner Only Release

June 3, 2016

Amgen Receives Positive CHMP Opinion to Extend Indication of Kyprolis® (Carfilzomib) for the Treatment of Relapsed Multiple Myeloma

On May 27, 2016, Amgen (NASDAQ:AMGN) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis® (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.

For further information, visit the link below to the website for press release distributed by Amgen.

http://www.amgen.com/media/news-releases/2016/05/amgen-receives-positive-chmp-opinion- to-extend-indication-of-kyprolis-carfilzomib-for-the-treatment-of-relapsed-multiple-myeloma/

In Japan, Ono Pharmaceutical Co., Ltd. (ONO) entered into an exclusive license agreement with Onyx, now a wholly-owned subsidiary of Amgen, in September 2010 to develop and commercialize two compounds from Onyx's proteasome inhibitor development program, carfilzomib (for injection) and oprozomib (orally administered) for all oncology indications. ONO submitted an application for Manufacturing and Marketing Approval of carfilzomib (ONO-7057) for the indication of relapsed or refractory multiple myeloma in August 2015.

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications public_relations@ono.co.jp